Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pliant Therapeutics, Inc. - Common Stock (NQ:PLRX)

1.150 +0.030 (+2.68%)
Streaming Delayed Price Updated: 1:44 PM EDT, Aug 21, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pliant Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Pliant Therapeutics Announces Positive Long-Term Data from the INTEGRIS-IPF Phase 2a Trial Demonstrating Bexotegrast was Well Tolerated at 320 mg with Durable Improvement Shown in FVC and Across Multiple Measures
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For April 13, 2023 ↗
 
Via Benzinga
News headline image
Expert Ratings for Pliant Therapeutics ↗
 
Via Benzinga
News headline image
The Latest Analyst Ratings for Pliant Therapeutics ↗
 
Via Benzinga
News headline image
9 Analysts Have This to Say About Pliant Therapeutics ↗
 
Via Benzinga
News headline image
Pliant Therapeutics to Participate in the 22nd Annual Needham Healthcare Conference
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
7 Biotech Stocks to Buy for 100% Returns ↗
If you can handle the risks associated with high volatility, these biotech stocks to buy might double the returns in your portfolio. 
Via InvestorPlace
News headline image
Pliant Therapeutics Announces Poster Presentations at the 2023 American Thoracic Society International Conference
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
Pliant Therapeutics Announces Positive DSMB Safety Review and Initiation of Enrollment of Phase 2a Trial of Bexotegrast (PLN-74809) at 320 mg Dose in Primary Sclerosing Cholangitis
Recent independent Data Safety Monitoring Board (DSMB) review recommended the INTEGRIS-PSC Phase 2a trial continue without modification and proceed to evaluate 320 mg dose 
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
Why Pliant Therapeutics Stock Is Skyrocketing This Week ↗
The company's experimental idiopathic pulmonary fibrosis drug is showing a lot of promise. 
Via The Motley Fool
News headline image
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2022 Financial Results
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
Pliant Therapeutics Announces Appointments of Darren Cline and Thomas McCourt to Board of Directors
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
Pliant Therapeutics to Participate in Upcoming Investor Events
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
Novartis Takes Down $80M NASH Pact With Pliant Therapeutics ↗
 
Via Benzinga
Expert Ratings for Pliant Therapeutics ↗
 
Via Benzinga
News headline image
An Unexpected Feat Just Sent Pliant Therapeutics Soaring More Than 50% ↗
The company has a potentially best-in-class approach to a lung condition. 
Via Investor's Business Daily
News headline image
Pliant Therapeutics to Participate in Upcoming Investor Events
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
Pliant Therapeutics Announces FDA Clearance of Investigational New Drug Application for PLN-101095, A Novel Integrin Inhibitor for the Treatment of Solid Tumors
Phase 1 clinical study initiation expected in the second quarter of 2023 
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
Pliant Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
Pliant Therapeutics Announces Appointment of Lily Cheung as Chief Human Resources Officer
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
Pliant Therapeutics zoomed 34% higher and added to that gain in the next session.This followed good news about clinical trials for a lung-condition treatment. 
Via MarketBeat
News headline image
Pliant Therapeutics Announces Pricing of Upsized $250.0 Million Public Offering
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
Pliant Therapeutics Announces Proposed Public Offering of Common Stock
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
Nasdaq Rises 1.5%; Pliant Therapeutics Shares Spike Higher ↗
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 150 points on Monday. The Dow traded up 0.46% to 33,527.51 while the NASDAQ rose 1.55% to 11,313.03. The... 
Via Benzinga
News headline image
Dow, Nasdaq Boasting Triple-Digit Midday Lead ↗
Investors seem intent on leaving last week's losses behind, as earnings season heats up. 
Via Talk Markets
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
Why Evoqua Water Technologies Shares Are Trading Higher By 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
Gainers Intelligent Bio Solutions Inc. (NASDAQ: INBS) shares climbed 444.4% to $1.47 after the company announced it successfully completed the review of results from Milestone 7, a phase of its... 
Via Benzinga
News headline image
Dow Jumps Over 300 Points; Crude Oil Up 1% ↗
U.S. stocks traded higher midway through trading, with the Dow Jones gaining more than 30 points on Monday. The Dow traded up 0.94% to 33,687.69 while the NASDAQ rose 1.93% to 11,355.16. The S&P 500... 
Via Benzinga
News headline image
Pliant Therapeutics (NASDAQ: PLRX) Reports Positive Phase 2 Clinical Trial Data of Bexotegrast in Treatment of Idiopathic Pulmonary Fibrosis
Pliant Therapeutics, Inc. (NASDAQ: PLRX) is engaged as a clinical-stage biopharmaceutical company, which is focused on the research and development 
Via Spotlight Growth
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.